• Increasing your probability of success every step of the way

  • New product development and commercial launch are costly and full of risk. Each step has its own challenges and opportunities. Master them all with Quintiles.

    • Fully integrated biotech and pharmaceutical services
    • Leveraging data to turn insights into faster, better decisions
    • Expertise in all major therapeutic areas for disease, patient and market-specific issues
    • Global footprint, local insight – in over 60 countries
  • Our Perspectives

    slider image

    Harnessing the Power of the Digital Patient

    This white paper discusses how biopharmaceutical companies can harness the power of the digital patient when it engages them in the appropriate manner. Read white paper

    slider image

    Tomorrow’s Path to Improved Early-Phase Oncology Drug Development

    Maximizing quality and efficiency of go/no-go decisions in early-phase studies. Read white paper

    slider image

    EIU Emerging China

    This Economist Intelligence Unit study, sponsored by Quintiles, looks at China’s growing pharmaceutical market and its implications for the global life sciences sector. Read white paper here

    slider image

    Lifecycle Modeling and Simulation

    Modeling and simulation is poised to transform drug development across the entire lifecycle from discovery to commercialization. Read white paper here

    slider image

    Integration of Molecular Biomarkers into Clinical Development

    Quintiles experts in strategic drug development recommend using biomarkers in anti-cancer therapy research. Read white paper here


    Video Spotlights 

  • Knowing what matters to your market can help define your path forward

    With expertise in the full spectrum of pharmaceutical services, we know how each decision affects the next.

    Clinical and commercial are converging – and it’s bringing new value to product development. Read more

    It’s never too early – or too late – to start planning your market access strategy. Find out how

    Payers and regulators are wanting more evidence of how drugs perform in the real world. Learn more